Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL Looks Beyond Organic Growth To External Innovation

Executive Summary

CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.


Related Content

Stock Scan February 2018: Wet But Above Water
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
CSL Behring Nears Market With Easier-To-Administer HAE Prophylactic
Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Deal Watch: Taking Care Of Business Before J.P. Morgan
Scrip 100: R&D Paths Of Top 50 Pharma


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts